MedTrace Logo

Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）

NCT05113459 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-11-09

No results posted yet for this study

Summary

This trial is a multi-center, open, single-arm, superior phase II clinical study.

Conditions

Interventions

DRUG

Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy

disitamab vedotin：2.5mg/kg, iv,d1,q2w,6cycle PD-1(Sintilimab ):200mg,iv,d1,q2w,6cycle Capecitabine:1000mg/m2,po,bid,d1-14,q3w,4cycle

Sponsors & Collaborators

  • Guoxin Li

    lead OTHER

Principal Investigators

  • guoxin li, PhD · Southern Hospital of Southern Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-18
Primary Completion
2023-12-18
Completion
2024-06-18

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05113459 on ClinicalTrials.gov